Troriluzole (BHV-4157)
Phase 3Terminated 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Obsessive Compulsive Disorder
Conditions
Obsessive Compulsive Disorder
Trial Timeline
Mar 30, 2021 → Feb 13, 2026
NCT ID
NCT04708834About Troriluzole (BHV-4157)
Troriluzole (BHV-4157) is a phase 3 stage product being developed by Biohaven for Obsessive Compulsive Disorder. The current trial status is terminated. This product is registered under clinical trial identifier NCT04708834. Target conditions include Obsessive Compulsive Disorder.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04708834 | Phase 3 | Terminated |
Competing Products
17 competing products in Obsessive Compulsive Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Duloxetine | Eli Lilly | Approved | 85 |
| Fluvoxamine maleate + Placebo | AbbVie | Phase 3 | 77 |
| quetiapine fumarate + SSRI/Clomipramine | AstraZeneca | Phase 3 | 77 |
| Quetiapine | AstraZeneca | Phase 2 | 52 |
| Clomipramine (fluoxetine plus clomipramine) + Quetiapine (fluoxetine plus quetiapine) + Placebo (fluoxetine plus placebo) | Novartis | Approved | 85 |
| Bitopertin + Placebo + SSRI | Roche | Phase 2 | 52 |
| sertraline | Pfizer | Pre-clinical | 22 |
| pregabalin + Placebo | Pfizer | Approved | 84 |
| Sertraline + Levetiracetam + Placebo | UCB | Phase 2/3 | 62 |
| Escitalopram | Lundbeck | Approved | 82 |
| Escitalopram + Placebo oral tablet | Lundbeck | Approved | 82 |
| Valbenazine + Placebo | Neurocrine Biosciences | Phase 2 | 49 |
| RG1068 (Synthetic Human Secretin) | Repligen | Phase 2 | 49 |
| Troriluzole + Placebo | Biohaven | Phase 3 | 72 |
| Troriluzole + Placebo | Biohaven | Phase 3 | 72 |
| Troriluzole + Placebo | Biohaven | Phase 2/3 | 60 |
| Nitrous Oxide + Nitrogen | Brain Biotech | Phase 2 | 44 |